{
  "cells": [
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "iL-nXLrJ5Y9I",
        "outputId": "e3f3ce64-e37f-45fa-af11-57a83af534d7"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Looking in indexes: https://pypi.org/simple, https://us-python.pkg.dev/colab-wheels/public/simple/\n",
            "Requirement already satisfied: openai in /usr/local/lib/python3.10/dist-packages (0.27.6)\n",
            "Requirement already satisfied: langchain in /usr/local/lib/python3.10/dist-packages (0.0.165)\n",
            "Requirement already satisfied: requests>=2.20 in /usr/local/lib/python3.10/dist-packages (from openai) (2.28.2)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from openai) (4.65.0)\n",
            "Requirement already satisfied: aiohttp in /usr/local/lib/python3.10/dist-packages (from openai) (3.8.4)\n",
            "Requirement already satisfied: PyYAML>=5.4.1 in /usr/local/lib/python3.10/dist-packages (from langchain) (6.0)\n",
            "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.0.10)\n",
            "Requirement already satisfied: async-timeout<5.0.0,>=4.0.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (4.0.2)\n",
            "Requirement already satisfied: dataclasses-json<0.6.0,>=0.5.7 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.5.7)\n",
            "Requirement already satisfied: numexpr<3.0.0,>=2.8.4 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.8.4)\n",
            "Requirement already satisfied: numpy<2,>=1 in /usr/local/lib/python3.10/dist-packages (from langchain) (1.22.4)\n",
            "Requirement already satisfied: openapi-schema-pydantic<2.0,>=1.2 in /usr/local/lib/python3.10/dist-packages (from langchain) (1.2.4)\n",
            "Requirement already satisfied: pydantic<2,>=1 in /usr/local/lib/python3.10/dist-packages (from langchain) (1.10.7)\n",
            "Requirement already satisfied: tenacity<9.0.0,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (8.2.2)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (23.1.0)\n",
            "Requirement already satisfied: charset-normalizer<4.0,>=2.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (2.0.12)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (6.0.4)\n",
            "Requirement already satisfied: yarl<2.0,>=1.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (1.9.2)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (1.3.3)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (1.3.1)\n",
            "Requirement already satisfied: marshmallow<4.0.0,>=3.3.0 in /usr/local/lib/python3.10/dist-packages (from dataclasses-json<0.6.0,>=0.5.7->langchain) (3.19.0)\n",
            "Requirement already satisfied: marshmallow-enum<2.0.0,>=1.5.1 in /usr/local/lib/python3.10/dist-packages (from dataclasses-json<0.6.0,>=0.5.7->langchain) (1.5.1)\n",
            "Requirement already satisfied: typing-inspect>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from dataclasses-json<0.6.0,>=0.5.7->langchain) (0.8.0)\n",
            "Requirement already satisfied: typing-extensions>=4.2.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<2,>=1->langchain) (4.5.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (3.4)\n",
            "Requirement already satisfied: urllib3<1.27,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (1.26.15)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (2022.12.7)\n",
            "Requirement already satisfied: greenlet!=0.4.17 in /usr/local/lib/python3.10/dist-packages (from SQLAlchemy<3,>=1.4->langchain) (2.0.2)\n",
            "Requirement already satisfied: packaging>=17.0 in /usr/local/lib/python3.10/dist-packages (from marshmallow<4.0.0,>=3.3.0->dataclasses-json<0.6.0,>=0.5.7->langchain) (23.1)\n",
            "Requirement already satisfied: mypy-extensions>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from typing-inspect>=0.4.0->dataclasses-json<0.6.0,>=0.5.7->langchain) (1.0.0)\n"
          ]
        }
      ],
      "source": [
        "!pip3 install openai langchain"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "on5P4C455ffP",
        "outputId": "6d5f5cde-320f-4311-af59-e4ca710a328a"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Looking in indexes: https://pypi.org/simple, https://us-python.pkg.dev/colab-wheels/public/simple/\n",
            "Requirement already satisfied: google-cloud-secret-manager in /usr/local/lib/python3.10/dist-packages (2.16.1)\n",
            "Requirement already satisfied: google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0 in /usr/local/lib/python3.10/dist-packages (from google-cloud-secret-manager) (2.11.0)\n",
            "Requirement already satisfied: proto-plus<2.0.0dev,>=1.22.0 in /usr/local/lib/python3.10/dist-packages (from google-cloud-secret-manager) (1.22.2)\n",
            "Requirement already satisfied: protobuf!=3.20.0,!=3.20.1,!=4.21.0,!=4.21.1,!=4.21.2,!=4.21.3,!=4.21.4,!=4.21.5,<5.0.0dev,>=3.19.5 in /usr/local/lib/python3.10/dist-packages (from google-cloud-secret-manager) (3.20.3)\n",
            "Requirement already satisfied: grpc-google-iam-v1<1.0.0dev,>=0.12.4 in /usr/local/lib/python3.10/dist-packages (from google-cloud-secret-manager) (0.12.6)\n",
            "Requirement already satisfied: googleapis-common-protos<2.0dev,>=1.56.2 in /usr/local/lib/python3.10/dist-packages (from google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (1.59.0)\n",
            "Requirement already satisfied: google-auth<3.0dev,>=2.14.1 in /usr/local/lib/python3.10/dist-packages (from google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (2.17.3)\n",
            "Requirement already satisfied: requests<3.0.0dev,>=2.18.0 in /usr/local/lib/python3.10/dist-packages (from google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (2.28.2)\n",
            "Requirement already satisfied: grpcio<2.0dev,>=1.33.2 in /usr/local/lib/python3.10/dist-packages (from google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (1.54.0)\n",
            "Requirement already satisfied: grpcio-status<2.0dev,>=1.33.2 in /usr/local/lib/python3.10/dist-packages (from google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (1.48.2)\n",
            "Requirement already satisfied: cachetools<6.0,>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from google-auth<3.0dev,>=2.14.1->google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (5.3.0)\n",
            "Requirement already satisfied: pyasn1-modules>=0.2.1 in /usr/local/lib/python3.10/dist-packages (from google-auth<3.0dev,>=2.14.1->google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (0.3.0)\n",
            "Requirement already satisfied: six>=1.9.0 in /usr/local/lib/python3.10/dist-packages (from google-auth<3.0dev,>=2.14.1->google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (1.16.0)\n",
            "Requirement already satisfied: rsa<5,>=3.1.4 in /usr/local/lib/python3.10/dist-packages (from google-auth<3.0dev,>=2.14.1->google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (4.9)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0dev,>=2.18.0->google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (2.0.12)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0dev,>=2.18.0->google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (3.4)\n",
            "Requirement already satisfied: urllib3<1.27,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0dev,>=2.18.0->google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (1.26.15)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0dev,>=2.18.0->google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (2022.12.7)\n",
            "Requirement already satisfied: pyasn1<0.6.0,>=0.4.6 in /usr/local/lib/python3.10/dist-packages (from pyasn1-modules>=0.2.1->google-auth<3.0dev,>=2.14.1->google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.0->google-cloud-secret-manager) (0.5.0)\n"
          ]
        }
      ],
      "source": [
        "!pip3 install --upgrade google-cloud-secret-manager"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "OqM_64vl9xff",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "faa752f8-0923-422c-df90-b011429386dc"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Looking in indexes: https://pypi.org/simple, https://us-python.pkg.dev/colab-wheels/public/simple/\n",
            "Requirement already satisfied: weaviate-client in /usr/local/lib/python3.10/dist-packages (3.18.0)\n",
            "Requirement already satisfied: requests<2.29.0,>=2.28.0 in /usr/local/lib/python3.10/dist-packages (from weaviate-client) (2.28.2)\n",
            "Requirement already satisfied: validators<=0.21.0,>=0.18.2 in /usr/local/lib/python3.10/dist-packages (from weaviate-client) (0.19.0)\n",
            "Requirement already satisfied: tqdm<5.0.0,>=4.59.0 in /usr/local/lib/python3.10/dist-packages (from weaviate-client) (4.65.0)\n",
            "Requirement already satisfied: authlib>=1.1.0 in /usr/local/lib/python3.10/dist-packages (from weaviate-client) (1.2.0)\n",
            "Requirement already satisfied: cryptography>=3.2 in /usr/local/lib/python3.10/dist-packages (from authlib>=1.1.0->weaviate-client) (40.0.2)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<2.29.0,>=2.28.0->weaviate-client) (2.0.12)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<2.29.0,>=2.28.0->weaviate-client) (3.4)\n",
            "Requirement already satisfied: urllib3<1.27,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<2.29.0,>=2.28.0->weaviate-client) (1.26.15)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<2.29.0,>=2.28.0->weaviate-client) (2022.12.7)\n",
            "Requirement already satisfied: decorator>=3.4.0 in /usr/local/lib/python3.10/dist-packages (from validators<=0.21.0,>=0.18.2->weaviate-client) (4.4.2)\n",
            "Requirement already satisfied: cffi>=1.12 in /usr/local/lib/python3.10/dist-packages (from cryptography>=3.2->authlib>=1.1.0->weaviate-client) (1.15.1)\n",
            "Requirement already satisfied: pycparser in /usr/local/lib/python3.10/dist-packages (from cffi>=1.12->cryptography>=3.2->authlib>=1.1.0->weaviate-client) (2.21)\n"
          ]
        }
      ],
      "source": [
        "!pip install --upgrade weaviate-client"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "HPEcnVk65p_j"
      },
      "outputs": [],
      "source": [
        "from google.colab import auth\n",
        "from google.cloud import secretmanager_v1beta1 as secretmanager\n",
        "\n",
        "import os"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "bRIV0boH5sf6"
      },
      "outputs": [],
      "source": [
        "auth.authenticate_user()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Zpsz0fzR5ul8",
        "outputId": "71311b90-f9e3-4ef3-a3f4-ba12e6e83efe"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Updated property [core/project].\n"
          ]
        }
      ],
      "source": [
        "!gcloud config set project muspelheim"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "ghqY9JFR53g-"
      },
      "outputs": [],
      "source": [
        "def access_secret_version(project_id, secret_id, version_id):\n",
        "    client = secretmanager.SecretManagerServiceClient()\n",
        "    secret_version_name = f\"projects/{project_id}/secrets/{secret_id}/versions/{version_id}\"\n",
        "    \n",
        "    response = client.access_secret_version(request={\"name\": secret_version_name})\n",
        "    secret_payload = response.payload.data.decode(\"UTF-8\")\n",
        "    \n",
        "    return secret_payload"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "fLUJeYAR6H7e"
      },
      "outputs": [],
      "source": [
        "OPENAPI_KEY = access_secret_version(\"muspelheim\", \"openai_key\", \"2\")\n",
        "os.environ['OPENAI_API_KEY']=OPENAPI_KEY"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 113,
      "metadata": {
        "id": "k7uFQRRf8CBi"
      },
      "outputs": [],
      "source": [
        "# WEAVIATE_KEY = \"qn4i7LWr5G7NK2nXNYzuHnrV0J824Rj0Ur8R\"\n",
        "WEAVIATE_CLUSTER = \"https://pgx-weaviate-hackathon-e702ovox.weaviate.network\""
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "jFzRaM6BDd_H"
      },
      "outputs": [],
      "source": [
        "import json\n",
        "import weaviate\n",
        "from bs4 import BeautifulSoup\n",
        "from pprint import pprint\n",
        "from langchain.prompts import PromptTemplate\n",
        "from langchain import OpenAI\n",
        "from langchain.chains import LLMChain, SimpleSequentialChain"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "llm = OpenAI(temperature=0.1, \n",
        "             model_name='gpt-3.5-turbo')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "k63LUgYhw8qG",
        "outputId": "854adf91-3880-4537-e43a-3fbd477ad2d8"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/langchain/llms/openai.py:169: UserWarning: You are trying to use a chat model. This way of initializing it is no longer supported. Instead, please use: `from langchain.chat_models import ChatOpenAI`\n",
            "  warnings.warn(\n",
            "/usr/local/lib/python3.10/dist-packages/langchain/llms/openai.py:696: UserWarning: You are trying to use a chat model. This way of initializing it is no longer supported. Instead, please use: `from langchain.chat_models import ChatOpenAI`\n",
            "  warnings.warn(\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 114,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "lUU6iPJtDSlt",
        "outputId": "27be5b35-a8d3-411b-84d8-0376dfd53239"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "metadata": {},
          "execution_count": 114
        }
      ],
      "source": [
        "client = weaviate.Client(\n",
        "    url=WEAVIATE_CLUSTER,\n",
        "    # auth_client_secret=weaviate.auth.AuthApiKey(api_key=WEAVIATE_KEY),\n",
        "    additional_headers={\n",
        "        \"X-OpenAI-Api-Key\": os.getenv(\"OPENAI_API_KEY\")\n",
        "    }\n",
        ")\n",
        "\n",
        "client.is_ready()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 112,
      "metadata": {
        "id": "IlVaoIZA8GCN"
      },
      "outputs": [],
      "source": [
        "pharmgkb_guideline_schema = {\n",
        "  \"class\": \"Guideline\",\n",
        "  \"description\": \"A collection of clinical guidelines collected by PharmGKB\",\n",
        "  \"vectorizer\": \"text2vec-openai\",\n",
        "  \"moduleConfig\": {\n",
        "    \"text2vec-openai\": {\n",
        "      \"model\": \"ada\",\n",
        "      \"modelVersion\": \"002\",\n",
        "      \"type\": \"text\"\n",
        "    },\n",
        "    \"generative-openai\": {\n",
        "        \"model\": \"gpt-3.5-turbo\",\n",
        "    }\n",
        "  },\n",
        "  \"properties\": [\n",
        "    {\n",
        "      \"name\": \"guideline_id\",\n",
        "      \"description\": \"PharmGKB Guideline ID\",\n",
        "      \"dataType\": [\"text\"]\n",
        "    },\n",
        "    {\n",
        "      \"name\": \"name\",\n",
        "      \"description\": \"Name of PharmGKB Guideline\",\n",
        "      \"dataType\": [\"text\"]\n",
        "    },\n",
        "    {\n",
        "      \"name\": \"relatedChemicals\",\n",
        "      \"description\": \"A list of chemicals that are related to the guideline\",\n",
        "      \"dataType\": [\"text[]\"]\n",
        "    },\n",
        "    {\n",
        "      \"name\": \"relatedGenes\",\n",
        "      \"description\": \"A list of genes that are related to the guideline\",\n",
        "      \"dataType\": [\"text[]\"]\n",
        "    },\n",
        "    {\n",
        "      \"name\": \"guideline\",\n",
        "      \"description\": \"The full text of the guideline in Markdown format\",\n",
        "      \"dataType\": [\"text\"]\n",
        "    },\n",
        "    {\n",
        "      \"name\": \"algorithm\",\n",
        "      \"description\": \"The full text of the algorithm\",\n",
        "      \"dataType\": [\"text\"]\n",
        "    }\n",
        "  ]\n",
        "}\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 115,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "G8S81xEoDp2w",
        "outputId": "31c351be-35ee-4cdb-ed92-417151ced9d3"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'classes': [{'class': 'Guideline',\n",
              "   'description': 'A collection of clinical guidelines collected by PharmGKB',\n",
              "   'invertedIndexConfig': {'bm25': {'b': 0.75, 'k1': 1.2},\n",
              "    'cleanupIntervalSeconds': 60,\n",
              "    'stopwords': {'additions': None, 'preset': 'en', 'removals': None}},\n",
              "   'moduleConfig': {'generative-openai': {'model': 'gpt-3.5-turbo'},\n",
              "    'text2vec-openai': {'model': 'ada',\n",
              "     'modelVersion': '002',\n",
              "     'type': 'text',\n",
              "     'vectorizeClassName': True}},\n",
              "   'properties': [{'dataType': ['text'],\n",
              "     'description': 'PharmGKB Guideline ID',\n",
              "     'indexFilterable': True,\n",
              "     'indexSearchable': True,\n",
              "     'moduleConfig': {'text2vec-openai': {'skip': False,\n",
              "       'vectorizePropertyName': False}},\n",
              "     'name': 'guideline_id',\n",
              "     'tokenization': 'word'},\n",
              "    {'dataType': ['text'],\n",
              "     'description': 'Name of PharmGKB Guideline',\n",
              "     'indexFilterable': True,\n",
              "     'indexSearchable': True,\n",
              "     'moduleConfig': {'text2vec-openai': {'skip': False,\n",
              "       'vectorizePropertyName': False}},\n",
              "     'name': 'name',\n",
              "     'tokenization': 'word'},\n",
              "    {'dataType': ['text[]'],\n",
              "     'description': 'A list of chemicals that are related to the guideline',\n",
              "     'indexFilterable': True,\n",
              "     'indexSearchable': True,\n",
              "     'moduleConfig': {'text2vec-openai': {'skip': False,\n",
              "       'vectorizePropertyName': False}},\n",
              "     'name': 'relatedChemicals',\n",
              "     'tokenization': 'word'},\n",
              "    {'dataType': ['text[]'],\n",
              "     'description': 'A list of genes that are related to the guideline',\n",
              "     'indexFilterable': True,\n",
              "     'indexSearchable': True,\n",
              "     'moduleConfig': {'text2vec-openai': {'skip': False,\n",
              "       'vectorizePropertyName': False}},\n",
              "     'name': 'relatedGenes',\n",
              "     'tokenization': 'word'},\n",
              "    {'dataType': ['text'],\n",
              "     'description': 'The full text of the guideline in Markdown format',\n",
              "     'indexFilterable': True,\n",
              "     'indexSearchable': True,\n",
              "     'moduleConfig': {'text2vec-openai': {'skip': False,\n",
              "       'vectorizePropertyName': False}},\n",
              "     'name': 'guideline',\n",
              "     'tokenization': 'word'},\n",
              "    {'dataType': ['text'],\n",
              "     'description': 'The full text of the algorithm',\n",
              "     'indexFilterable': True,\n",
              "     'indexSearchable': True,\n",
              "     'moduleConfig': {'text2vec-openai': {'skip': False,\n",
              "       'vectorizePropertyName': False}},\n",
              "     'name': 'algorithm',\n",
              "     'tokenization': 'word'}],\n",
              "   'replicationConfig': {'factor': 1},\n",
              "   'shardingConfig': {'virtualPerPhysical': 128,\n",
              "    'desiredCount': 1,\n",
              "    'actualCount': 1,\n",
              "    'desiredVirtualCount': 128,\n",
              "    'actualVirtualCount': 128,\n",
              "    'key': '_id',\n",
              "    'strategy': 'hash',\n",
              "    'function': 'murmur3'},\n",
              "   'vectorIndexConfig': {'skip': False,\n",
              "    'cleanupIntervalSeconds': 300,\n",
              "    'maxConnections': 64,\n",
              "    'efConstruction': 128,\n",
              "    'ef': -1,\n",
              "    'dynamicEfMin': 100,\n",
              "    'dynamicEfMax': 500,\n",
              "    'dynamicEfFactor': 8,\n",
              "    'vectorCacheMaxObjects': 1000000000000,\n",
              "    'flatSearchCutoff': 40000,\n",
              "    'distance': 'cosine',\n",
              "    'pq': {'enabled': False,\n",
              "     'bitCompression': False,\n",
              "     'segments': 0,\n",
              "     'centroids': 256,\n",
              "     'encoder': {'type': 'kmeans', 'distribution': 'log-normal'}}},\n",
              "   'vectorIndexType': 'hnsw',\n",
              "   'vectorizer': 'text2vec-openai'}]}"
            ]
          },
          "metadata": {},
          "execution_count": 115
        }
      ],
      "source": [
        "client.schema.delete_all()\n",
        "client.schema.get()\n",
        "\n",
        "client.schema.create_class(pharmgkb_guideline_schema)\n",
        "\n",
        "client.schema.get()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "NOT41rdYOTHY"
      },
      "outputs": [],
      "source": [
        "def html_to_text(html_string):\n",
        "  soup = BeautifulSoup(html_string, \"html.parser\")\n",
        "  text = soup.get_text()\n",
        "  return text"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "9Qb1FA3hLlOI"
      },
      "outputs": [],
      "source": [
        "def transform_guideline(content):\n",
        "  guideline = content['guideline']\n",
        "  record = {}\n",
        "  #   {\n",
        "  #   \"name\": \"guideline_id\",\n",
        "  #   \"description\": \"PharmGKB Guideline ID\",\n",
        "  #   \"dataType\": [\"text\"]\n",
        "  # },\n",
        "  record[\"guideline_id\"] = guideline['id']\n",
        "  # {\n",
        "  #   \"name\": \"name\",\n",
        "  #   \"description\": \"Name of PharmGKB Guideline\",\n",
        "  #   \"dataType\": [\"text\"]\n",
        "  # },\n",
        "  record[\"name\"] = guideline['name']\n",
        "  # {\n",
        "  #   \"name\": \"relatedChemicals\",\n",
        "  #   \"description\": \"A list of chemicals that are related to the guideline\",\n",
        "  #   \"dataType\": [\"text[]\"]\n",
        "  # },\n",
        "  record[\"relatedChemicals\"] = [related_chemical['name'] for related_chemical in guideline['relatedChemicals']]\n",
        "  # {\n",
        "  #   \"name\": \"relatedGenes\",\n",
        "  #   \"description\": \"A list of genes that are related to the guideline\",\n",
        "  #   \"dataType\": [\"text[]\"]\n",
        "  # },\n",
        "  record[\"relatedGenes\"] = [related_gene['symbol'] for related_gene in guideline['relatedGenes']]\n",
        "  # {\n",
        "  #   \"name\": \"guideline\",\n",
        "  #   \"description\": \"The full text of the guideline in Markdown format\",\n",
        "  #   \"dataType\": [\"text\"]\n",
        "  # }\n",
        "  record[\"guideline\"] = html_to_text(guideline['summaryMarkdown']['html'])\n",
        "\n",
        "  return record\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "Muu0wEK5EW7v"
      },
      "outputs": [],
      "source": [
        "guidelines = []\n",
        "\n",
        "guidelines_directory = \"/content/drive/MyDrive/pgx/guidelineAnnotations.json\"\n",
        "files = [f for f in os.listdir(guidelines_directory) if f.endswith(\".json\")]\n",
        "\n",
        "for file in files:\n",
        "  filename = f\"{guidelines_directory}/{file}\"\n",
        "  with open(filename) as f:\n",
        "    content = json.load(f)\n",
        "    if content['guideline'][\"recommendation\"]:\n",
        "      guideline = transform_guideline(content)\n",
        "      guidelines.append(guideline)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def guideline_to_algorithmn(guideline):\n",
        "  prompt = PromptTemplate(\n",
        "    input_variables=[\"guideline\"],\n",
        "    template=\"Please turn the following guideline into an algorithm for an LLM: {guideline}\",\n",
        "  )\n",
        "  \n",
        "  prompt_text = prompt.format(guideline=guideline)\n",
        "\n",
        "  print(f\"\\n{prompt_text}:\")\n",
        "  return llm(prompt_text)"
      ],
      "metadata": {
        "id": "fzL0jTp1wb_8"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "guidelines_with_algo = []\n",
        "for guideline in guidelines:\n",
        "  try:\n",
        "    guideline_stmt = \"\"\"\n",
        "    This guideline applies to the following medications: {}\n",
        "    This guideline applies to the following genes: {}\n",
        "\n",
        "    Guideline:\n",
        "    {}\n",
        "    \"\"\".format(\", \".join(guideline['relatedChemicals']),\n",
        "               \", \".join(guideline['relatedGenes']),\n",
        "               guideline['guideline'])\n",
        "    algo = guideline_to_algorithmn(guideline_stmt)\n",
        "    guideline['algorithm'] = algo\n",
        "    guidelines_with_algo.append(guideline)\n",
        "  except Exception as e:\n",
        "    print(e)"
      ],
      "metadata": {
        "id": "ymFgxBzFxmsE",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "92397874-d750-4ae2-ff52-a5e2022bb3f8"
      },
      "execution_count": 107,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: clomipramine\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to avoid clomipramine in CYP2C19 ultrarapid metabolizer (UM) for Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: warfarin\n",
            "    This guideline applies to the following genes: VKORC1\n",
            "\n",
            "    Guideline:\n",
            "    Patients with the VKORC1 rs9923231 TT genotype (-1639 AA genotype) should be given 60% of the standard initial dose of warfarin. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. There are no recommendation for patients with the VKORC1 rs9923231 CT genotype (-1639 AG genotype).\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: azathioprine\n",
            "    This guideline applies to the following genes: NUDT15, TPMT\n",
            "\n",
            "    Guideline:\n",
            "    Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: rasburicase\n",
            "    This guideline applies to the following genes: G6PD\n",
            "\n",
            "    Guideline:\n",
            "    Rasburicase is contraindicated in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a negative or inconclusive genetic test result an enzyme activity test is recommended prior to rasburicase treatment to determine whether a patient is G6PD deficient. The G6PD gene is X-linked and therefore males only have one copy, whereas females have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: simvastatin\n",
            "    This guideline applies to the following genes: SLCO1B1\n",
            "\n",
            "    Guideline:\n",
            "    Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: celecoxib, flurbiprofen, ibuprofen, lornoxicam\n",
            "    This guideline applies to the following genes: CYP2C9\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of\n",
            "the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: dexlansoprazole\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: voriconazole\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: ivacaftor\n",
            "    This guideline applies to the following genes: CFTR\n",
            "\n",
            "    Guideline:\n",
            "    Ivacaftor treatment is recommended only in cystic fibrosis (CF) patients that are either homozygous or heterozygous for certain CFTR variants.  See full guideline for disclaimers, further details and supporting evidence.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: clopidogrel\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy for CYP2C19 poor or intermediate metabolizers (cardiovascular indications: prasugrel or ticagrelor if no contraindication; neurovascular indications: alternative P2Y12 inhibitor if clinically indicated and no contraindication.)\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: oxcarbazepine\n",
            "    This guideline applies to the following genes: HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for oxcarbazepine recommends an alternative drug for oxcarbazepine-naive patients carrying at least one copy of HLA-B*15:02 due to the association of this allele with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: atazanavir\n",
            "    This guideline applies to the following genes: UGT1A1\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC dosing guideline recommends considering advising individuals who carry two decreased function UGT1A1 alleles about a substantial likelihood of developing jaundice, which may cause non-adherence. The dosing guideline recommends that alternative agents be considered if the risk of non-adherence due to jaundice is high. The risk of discontinuation is low and very low for individuals carrying one, or no decreased function UGT1A1 alleles, respectively.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: ondansetron\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC dosing guideline for ondansetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: lansoprazole, omeprazole, pantoprazole\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: meloxicam\n",
            "    This guideline applies to the following genes: CYP2C9\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: quetiapine\n",
            "    This guideline applies to the following genes: CYP3A4\n",
            "\n",
            "    Guideline:\n",
            "    Patients who are CYP3A4 poor metabolizers and being treated for depression should be given an alternative drug. Patients being treated for other indications and who are CYP3A4 poor metabolizers should be given a reduced dose of quetiapine. No action is needed for patients who are CYP3A4 intermediate metabolizers.\n",
            "PharmGKB uses CYP3A4 allele nomenclature as defined by PharmVar, while the current version of this guideline issued by the DPWG uses retired allele names. Further details are given on the DPWG curation page.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: tamoxifen\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published clinical practice guidelines for CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients. The guidelines recommend that alternatives to standard tamoxifen treatments may be considered in CYP2D6 poor or intermediate metabolizers with an emphasis on the use of comprehensive CYP2D6 genotyping panels in guiding treatment decisions.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: simvastatin\n",
            "    This guideline applies to the following genes: SLCO1B1\n",
            "\n",
            "    Guideline:\n",
            "    Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If simvastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: risperidone\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The Dutch Pharmacogenetics Working Group Guideline for risperidone recommends decreasing the dose for CYP2D6 poor metabolizers and using an alternative drug or titrate the dose according to the maximum dose for the active metabolite for CYP2D6 ultrarapid metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: efavirenz\n",
            "    This guideline applies to the following genes: CYP2B6\n",
            "\n",
            "    Guideline:\n",
            "    Consider initiating efavirenz with a decreased dose of either 400 or 200 mg/day for patients who are CYP2B6 poor metabolizers. Consider initiating efavirenz with a decreased dose of 400 mg/day for patients who are CYP2B6 intermediate metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: tramadol\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    Alternate non-codeine analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of tramadol is warranted for CYP2D6 normal and intermediate metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: piroxicam\n",
            "    This guideline applies to the following genes: CYP2C9\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: venlafaxine\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    For CYP2D6 poor (PM) and intermediate metabolizers (IM), select an alternative to venlafaxine or reduce the dose and monitor patient's plasma metabolite level. For CYP2D6 ultrarapid metabolizers (UM), increase dose to 150% of the normal dose or select an alternative to venlafaxine.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: lansoprazole\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 4-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 4-fold higher dose.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: acenocoumarol, fluindione, warfarin\n",
            "    This guideline applies to the following genes: CYP2C9, VKORC1\n",
            "\n",
            "    Guideline:\n",
            "    Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: aripiprazole\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: clopidogrel\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    Testing for the main CYP2C19 deficiency alleles before instituting clopidogrel treatment is recommended (a test is essential for coronary angioplasty with stenting and based on the current state of knowledge this test is potentially useful in the other indications). For patients carrying at least one deficiency allele, the RNPGx recommends using an alternative treatment that is not a CYP2C19 substrate (eg. prasugrel, ticagrelor).\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: codeine\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of CYP2D6 genotype when prescribing codeine. They recommend that poor metabolizers of CYP2D6 should not receive codeine for pain relief, and ultrametabolizers of CYP2D6 should avoid codeine for pain relief.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: fluvoxamine\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor fluvoxamine recommends to consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6 for CYP2D6 poor metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: propafenone\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    Reduce the dose of propafenone by 70% for CYP2D6 poor metabolizers, and monitor propafenone plasma concentrations or use an alternative drug for CYP2D6 intermediate and ultrarapid metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: hydrocodone\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    CYP2D6 intermediate and poor metabolizers should initiate hydrocodone therapy using the label recommended age- or weight-specific dosing. However, if there is no response to hydrocodone in these patients, an alternative analgesic should be considered.\n",
            "There is insufficient evidence to provide a dosing recommendation for hydrocodone in CYP2D6 ultrarapid metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine\n",
            "    This guideline applies to the following genes: CACNA1S, RYR1\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: paroxetine\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor paroxetine recommends an alternative drug not predominantly metabolized by CYP2D6 for CYP2D6 ultrarapid metabolizers and for CYP2D6 poor metabolizers. For CYP2D6 poor metabolizers, if paroxetine use is warranted, consider a 50% reduction of recommended starting dose and titrate to response.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: codeine\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    Alternate non-tramadol analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of codeine is warranted for CYP2D6 normal and intermediate metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: daunorubicin, doxorubicin\n",
            "    This guideline applies to the following genes: RARG, SLC28A3, UGT1A6\n",
            "\n",
            "    Guideline:\n",
            "    The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT).\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: sertraline\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor sertraline recommends to consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 poor metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: hmg coa reductase inhibitors, simvastatin\n",
            "    This guideline applies to the following genes: SLCO1B1\n",
            "\n",
            "    Guideline:\n",
            "    Testing for rs4149056 before starting statin treatment, or early after treatment onset (potentially useful test) is recommended in patients with one or more risk factors described (as a function of statin type and dose, co-medications, and the pathophysiological or genetic setting). If the genotype is not known early, the RNPGx considers that a polymorphism test is potentially useful in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic cause.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: fluorouracil\n",
            "    This guideline applies to the following genes: DPYD\n",
            "\n",
            "    Guideline:\n",
            "    An alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as \"essential\" and recommend DPYD testing prior to initiating fluoropyrimidines.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: brexpiprazole\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to use half of the standard dose of brexpiprazole for patients carrying poor metabolizer alleles of CYP2D6.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: carbamazepine\n",
            "    This guideline applies to the following genes: HLA-A, HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline update for carbamazepine recommends an alternative drug for carbamazepine-naive patients carrying at least one copy of either HLA-B*15:02 or HLA-A*31:01 due to the association of those alleles with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, HLA-A*31:01 is associated with an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE).\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: mercaptopurine\n",
            "    This guideline applies to the following genes: TPMT\n",
            "\n",
            "    Guideline:\n",
            "    Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: oxcarbazepine\n",
            "    This guideline applies to the following genes: HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    Oxcarbazepine should be avoided if an alternative is available in patients with the HLA-B*15:02 allele.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: mercaptopurine\n",
            "    This guideline applies to the following genes: NUDT15\n",
            "\n",
            "    Guideline:\n",
            "    Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: azathioprine\n",
            "    This guideline applies to the following genes: NUDT15\n",
            "\n",
            "    Guideline:\n",
            "    Select an alternative drug or reduce the initial dose of azathioprine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: sertraline\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    Do not give doses exceeding 75 mg/day in patients with CYP2C19 poor metabolizer genotypes, and guide the dose by response and side effects and/or sertraline plasma concentration.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: capecitabine, fluorouracil\n",
            "    This guideline applies to the following genes: DPYD\n",
            "\n",
            "    Guideline:\n",
            "    The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for DPYD deficiency before initiating a treatment regimen based on 5-FU or capecitabine, with dose reductions for DPYD partial deficiency and contraindicates fluoropyrimidines in patients with complete deficiency.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: cisplatin\n",
            "    This guideline applies to the following genes: TPMT\n",
            "\n",
            "    Guideline:\n",
            "    The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for TPMT gene variants when prescribing cisplatin in pediatric cancer patients. They recommend testing for the TPMT alleles *2, *3A, *3B or *3C in all pediatric cancer patients due to the association of these alleles with an increased risk of cisplatin-induced ototoxicity.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: lamotrigine\n",
            "    This guideline applies to the following genes: HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    Avoid lamotrigine in patients with HLA-B*1502 if an alternative is available. If avoidance is not possible, advise to report any rash immediately.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: allopurinol\n",
            "    This guideline applies to the following genes: HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    Individuals with the HLA-B*58:01 allele should be given an alternative drug or undergo induction of allopurinol tolerance.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: metoprolol\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    For CYP2D6 poor and intermediate metabolizer patients, if a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA, use smaller steps in dose titration and/or prescribe no more than 25% or 50% of the standard dose, respectively. For CYP2D6 ultra metabolizers, use the maximum dose for the relevant indication as a target dose, and if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative drug.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: fosphenytoin, phenytoin\n",
            "    This guideline applies to the following genes: CYP2C9, HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (\"HLA-B*15:02-positive\") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: carbamazepine\n",
            "    This guideline applies to the following genes: HLA-A\n",
            "\n",
            "    Guideline:\n",
            "    Consider an alternative drug to carbamazepine in patients with the HLA-A*3101 allele.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: flucytosine\n",
            "    This guideline applies to the following genes: DPYD\n",
            "\n",
            "    Guideline:\n",
            "    The Dutch Pharmacogenetics Working Group Guideline for flucytosine states that patients with a DPYD activity score of 0 should avoid flucytosine. Patients with a DPYD activity score of 1 or 1.5 should be alert to the occurrence of severe side effects and flucytosine should be stopped if severe side effects occur.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: mercaptopurine\n",
            "    This guideline applies to the following genes: TPMT\n",
            "\n",
            "    Guideline:\n",
            "    The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for TPMT.\n",
            "\n",
            "    :\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:langchain.llms.openai:Retrying langchain.llms.openai.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: That model is currently overloaded with other requests. You can retry your request, or contact us through our help center at help.openai.com if the error persists. (Please include the request ID f3da4fa00e17462786806e7193b20b23 in your message.).\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: warfarin\n",
            "    This guideline applies to the following genes: CYP2C9\n",
            "\n",
            "    Guideline:\n",
            "    Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. \"The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins\"\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: nortriptyline\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: carbamazepine\n",
            "    This guideline applies to the following genes: HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    Consider an alternative drug to carbamazepine in patients with the HLA-B*1502 0r HLA-B*1511 alleles.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: warfarin\n",
            "    This guideline applies to the following genes: CYP2C9\n",
            "\n",
            "    Guideline:\n",
            "    The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for variants in VKORC1 and CYP2C9 in adult and pediatric patients with an indication for warfarin. They recommend testing for the VKORC1 SNP -1639G>A (rs9923231) and the CYP2C9 alleles *2 and *3 in order to better guide warfarin dosage.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: clopidogrel\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    Avoid clopidogrel use in patients who are CYP2C19 poor metabolizers and are undergoing percutaneous coronary intervention, stroke or TIA. For CYP2C19 intermediate metabolizers who are undergoing percutaneous coronary intervention, stroke, or TIA, choose an alternative drug or double the dose to 150 mg/day (600 mg loading dose). No action is required for patients who are CYP2C19 ultra-rapid metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: pantoprazole\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 5-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 5-fold higher dose.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: hormonal contraceptives for systemic use\n",
            "    This guideline applies to the following genes: F5\n",
            "\n",
            "    Guideline:\n",
            "    In individuals who carry the Factor V Leiden allele (rs6025 T) and have a family history of thrombotic events, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: capecitabine\n",
            "    This guideline applies to the following genes: DPYD\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A>T];[2846A>T] genotype may require a >50% dose reduction.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: azathioprine\n",
            "    This guideline applies to the following genes: TPMT\n",
            "\n",
            "    Guideline:\n",
            "    Select an alternative drug or reduce the initial dose of azathioprine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: imipramine\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    CYP2C19 poor metabolizers should receive 70% of the standard dose of imipramine, or imipramine should be avoided in these patients. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: tacrolimus\n",
            "    This guideline applies to the following genes: CYP3A5\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC dosing guideline for tacrolimus recommends increasing the starting dose by 1.5 to 2 times the recommended starting dose in patients who are CYP3A5 intermediate or extensive metabolizers, though total starting dose should not exceed 0.3 mg/kg/day. Therapeutic drug monitoring should also be used to guide dose adjustments.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: tamoxifen\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    For CYP2D6 poor and intermediate metabolizers, consider an alternative medication or a dose increase. For intermediate metabolizers, avoid concomitant CYP2D6 inhibitor use.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: haloperidol\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The recommendation for CYP2D6 poor metabolizers is to use 60% of the standard dose of haloperidol and for CYP2D6 ultrarapid metabolizers to use 1.5 times the standard dose or to choose an alternative to haloperidol.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: tegafur\n",
            "    This guideline applies to the following genes: DPYD\n",
            "\n",
            "    Guideline:\n",
            "    Choose an alternative drug to tegafur for patients with DPYD Activity Score of 0. For patients with a DPYD Activity Score of 1 or 1.5, avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives for tegafur, as these are also metabolized by DPD. The DPWG evaluated DPYD genotyping as \"essential\" and recommend DPYD testing prior to initiating fluoropyrimidines.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: thioguanine\n",
            "    This guideline applies to the following genes: NUDT15\n",
            "\n",
            "    Guideline:\n",
            "    Select an alternative drug or reduce the initial dose of thioguanine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: capecitabine\n",
            "    This guideline applies to the following genes: DPYD\n",
            "\n",
            "    Guideline:\n",
            "    An alternative drug to capecitabine is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for capecitabine, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as \"essential\" and recommend DPYD testing prior to initiating fluoropyrimidines.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: siponimod\n",
            "    This guideline applies to the following genes: CYP2C9\n",
            "\n",
            "    Guideline:\n",
            "    The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for CYP2C9 *1/*3, *2/*3 genotypes and to avoid siponimod for the CYP2C9 *3/*3 genotype.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: phenprocoumon\n",
            "    This guideline applies to the following genes: VKORC1\n",
            "\n",
            "    Guideline:\n",
            "    Patients with the VKORC1 rs9923231 TT genotype (-1639 AA genotype) is recommended to be given 50% of the standard initial dose of phenprocoumon and more frequent monitoring of INR. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. There is no recommendation for patients with the VKORC1 rs9923231 CT genotype (-1639 AG genotype).\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: tramadol\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    Be alert to a reduced efficacy of tramadol in CYP2D6 intermediate or poor metabolizers. If tramadol is not effective in these patients, try a dose increase or select an alternative to tramadol (not codeine) and be alert for symptoms of insufficient pain relief. For CYP2D6 ultrarapid metabolizers, use an alternative to tramadol (not codeine) or use 40% of the standard dose and be alert to side effects.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: omeprazole\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 3-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 3-fold higher dose.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: imipramine\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    CYP2D6 poor metabolizers should receive 30% of the standard dose of imipramine, CYP2D6 intermediate metabolizers should receive 70% of the standard dose, and CYP2D6 ultra-rapid metabolizers should receive 1.7 times the standard dose. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: acenocoumarol\n",
            "    This guideline applies to the following genes: VKORC1\n",
            "\n",
            "    Guideline:\n",
            "    Patients with the VKORC1 rs9923231 TT genotype (-1639 AA genotype) should be given 50% of the standard initial dose of acenocoumarol and undergo more frequent INR monitoring. There are no recommendation for patients with the VKORC1 rs9923231 CT genotype (-1639 AG genotype).\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: thioguanine\n",
            "    This guideline applies to the following genes: TPMT\n",
            "\n",
            "    Guideline:\n",
            "    Select an alternative drug or reduce the initial dose of thioguanine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: abacavir\n",
            "    This guideline applies to the following genes: HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    Avoid abacavir for patients who have the HLA-B*57:01 allele (patients who are \"HLA-B*57:01-positive\").\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: irinotecan\n",
            "    This guideline applies to the following genes: UGT1A1\n",
            "\n",
            "    Guideline:\n",
            "    Dose reductions are recommended for irinotecan for patients who are UGT1A1 *28/*28 or UGT1A1 PM, starting with 70% of starting dose and increasing as tolerated, guided by neutrophil count.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: warfarin\n",
            "    This guideline applies to the following genes: CYP2C9, CYP4F2, VKORC1\n",
            "\n",
            "    Guideline:\n",
            "    The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: atomoxetine\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: tropisetron\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC dosing guideline for tropisetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: tamoxifen\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an activity score (AS) of 1 the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an AS of 1. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: clomipramine\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The Dutch Pharmacogenetics Working Group Guideline for clomipramine recommends dose changes and to monitor the effect and side effects and the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), and intermediate (IM) metabolizer or to avoid clomipramine in PM and ultrarapid (UM) metabolizer.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: nortriptyline\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The Dutch Pharmacogenetics Working Group Guideline for nortriptyline recommends a dose reduction for CYP2D6 poor or intermediate metabolizer patients. For CYP2D6 ultrarapid metabolizers, select an alternative drug or use 1.7 times the standard dose. Monitoring of nortriptyline and 10-hydroxynortriptyline plasma concentrations is recommended.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: thioguanine\n",
            "    This guideline applies to the following genes: NUDT15, TPMT\n",
            "\n",
            "    Guideline:\n",
            "    Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: mercaptopurine\n",
            "    This guideline applies to the following genes: NUDT15, TPMT\n",
            "\n",
            "    Guideline:\n",
            "    Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: tenoxicam\n",
            "    This guideline applies to the following genes: CYP2C9\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: fluorouracil\n",
            "    This guideline applies to the following genes: DPYD\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A>T];[2846A>T] genotype may require a >50% dose reduction.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: ivacaftor\n",
            "    This guideline applies to the following genes: CFTR\n",
            "\n",
            "    Guideline:\n",
            "    Ivacaftor is suggested for some cystic fibrosis patients with specific CFTR gating mutations, including the R117H or G551D variants.\n",
            "Note that the guideline also suggests that ivacaftor should not be used in patients with at least one R117H mutation who are aged under 6 years or aged 12-17 years and with ppFEV1 greater than 90% predicted.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: azathioprine\n",
            "    This guideline applies to the following genes: TPMT\n",
            "\n",
            "    Guideline:\n",
            "    Testing for TPMT genotype and phenotype is recommended for patients who are receiving azathioprine as an immunosuppressant. A dose reduction should be considered for patients with intermediate TPMT activity, while a greater dose reduction or selection of an alternate drug should be considered for patients with low TPMT activity.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: atorvastatin\n",
            "    This guideline applies to the following genes: SLCO1B1\n",
            "\n",
            "    Guideline:\n",
            "    Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: clomipramine\n",
            "    This guideline applies to the following genes: CYP2C19, CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: efavirenz\n",
            "    This guideline applies to the following genes: CYP2B6\n",
            "\n",
            "    Guideline:\n",
            "    Adjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with the *5/*6, *5/*18 or other CYP2B6 IM genotypes, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed.\n",
            "No action is required for patients with the *1/*5 or *5/*5 genotypes.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: flucloxacillin\n",
            "    This guideline applies to the following genes: HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    Monitor for liver function and select an alternative drug instead of flucloxacillin if liver enzymes or bilirubin is elevated, for patients that are HLA-B*5701.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: trimipramine\n",
            "    This guideline applies to the following genes: CYP2C19, CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: carbamazepine\n",
            "    This guideline applies to the following genes: HLA-A, HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of HLA-A*31:01 or HLA-B*15:02 genotype when prescribing carbamazepine (CBZ).  They recommend that carbamazepine not be prescribed for CBZ-naive patients who carry at least one HLA-A*31:01 or HLA-B*15:02 allele.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: voriconazole\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    Patients who are CYP2C19 poor metabolizers should receive 50% of the standard dose, and CYP2C19 ultrarapid metabolizers should receive a 1.5 times higher initial dose. Monitor voriconazole plasma concentrations for CYP2C19 poor, intermediate and ultrarapid metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: zuclopenthixol\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    For CYP2D6 poor and intermediate metabolizers, reduce zuclopenthixol dose or select an alternative drug that is not metabolized by CYP2D6. For ultrarapid metabolizers, be alert to low zuclopenthixol plasma concentrations and, if necessary, increase the dose or select an alternative drug.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: paroxetine\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    Select an alternative drug rather than paroxetine for CYP2D6 ultrarapid metabolizer patients.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: citalopram\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    The Dutch Pharmacogenetics Working Group Guideline for citalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified daily doses.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: tacrolimus\n",
            "    This guideline applies to the following genes: CYP3A5\n",
            "\n",
            "    Guideline:\n",
            "    Increased doses of tacrolimus are recommended for CYP3A5 heterozygous and homozygous expressors and adjusted as needed. Instructions for liver transplantation patients include genotypes of both patient and donor.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: amitriptyline\n",
            "    This guideline applies to the following genes: CYP2C19, CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: codeine\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The Pharmacogenetics Working Group Guideline for codeine includes individual recommendations for cough or pain for CYP2D6 poor, intermediate, and ultrarapid metabolizer. In addition, for ultrarapid metabolizer, higher or lower doses and additional risk factors are taken into consideration.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: amitriptyline\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The Dutch Pharmacogenetics Working Group Guideline for amitriptyline recommends decreasing the dose for CYP2D6 intermediate and CYP2D6 poor metabolizers and increasing the dose or using an alternative drug for CYP2D6 ultra-rapid metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: tacrolimus\n",
            "    This guideline applies to the following genes: CYP3A4, CYP3A5\n",
            "\n",
            "    Guideline:\n",
            "    Testing for the CYP3A5*3 and CYP3A4*22 alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: phenytoin\n",
            "    This guideline applies to the following genes: CYP2C9\n",
            "\n",
            "    Guideline:\n",
            "    Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: peginterferon alfa-2a, peginterferon alfa-2b, ribavirin\n",
            "    This guideline applies to the following genes: IFNL3\n",
            "\n",
            "    Guideline:\n",
            "    IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: eliglustat\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The Dutch Pharmacogenetics Working Group Guideline for eliglustat recommends to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers recommendations are provided for co-medication with CYP2D6 and/or CYP3A inhibitors and CYP3A inducers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: escitalopram\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    The Dutch Pharmacogenetics Working Group Guideline for escitalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified doses and for CYP2C19 ultrarapid metabolizer to avoid escitalopram.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: atomoxetine\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The Dutch Pharmacogenetics Working Group Guideline for atomoxetine states for CYP2D6 ultrarapid metabolizers, to be alert to reduced efficacy of atomoxetine or select an alternative drug as a precaution.  Be alert to ADEs in CYP2D6 poor metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: doxepin\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The Dutch Pharmacogenetics Working Group Guideline for doxepin recommends dose changes and to monitor the effect and side effects or the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM), and ultrarapid (UM) metabolizer or to avoid doxepin in UM.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: citalopram, escitalopram\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: flecainide\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    Reduce flecainide dose by 50% for CYP2D6 poor metabolizer (PM) and record an ECG and monitor the plasma concentration. Reduce flecainide dose to 75% of the standard dose for CYP2D6 intermediate metabolizer (IM) patients with indications other than diagnosis of Brugada syndrome and record an ECG and monitor the plasma concentration.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: allopurinol\n",
            "    This guideline applies to the following genes: HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (\"HLA-B*58:01-positive\") due to significantly increased risk of allopurinol-induced SCAR.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: irinotecan\n",
            "    This guideline applies to the following genes: UGT1A1\n",
            "\n",
            "    Guideline:\n",
            "    A French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published guidelines for the use of UGT1A1*28 genotype when prescribing irinotecan. They recommend that the dose of irinotecan be reduced in patients with the UGT1A1*28/*28 genotype, and that high-dose irinotecan (>=240 mg/m2) only be prescribed to patients with the UGT1A1*1/*1 genotype. The French National Network of Pharmacogenetics (RNPGx) included recommendations for irinotecan in  a 2017 paper on several anti-cancer drugs.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: capecitabine, fluorouracil, tegafur\n",
            "    This guideline applies to the following genes: DPYD\n",
            "\n",
            "    Guideline:\n",
            "    Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: allopurinol\n",
            "    This guideline applies to the following genes: ABCG2\n",
            "\n",
            "    Guideline:\n",
            "    Patients with the GT or TT genotypes at rs2231142 should be given an increased dose of allopurinol.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: pitavastatin\n",
            "    This guideline applies to the following genes: SLCO1B1\n",
            "\n",
            "    Guideline:\n",
            "    Prescribe ≤1mg as a starting dose for patients with SLCO1B1 poor function phenotype. Prescribe ≤2mg as a starting dose for patients with SLCO1B1 decreased or possible decreased phenotype. Adjust doses of pitavastatin based on disease-specific guidelines. Consider an alternative statin or combination therapy if higher doses are needed.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: fluvastatin\n",
            "    This guideline applies to the following genes: CYP2C9, SLCO1B1\n",
            "\n",
            "    Guideline:\n",
            "    CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: lovastatin\n",
            "    This guideline applies to the following genes: SLCO1B1\n",
            "\n",
            "    Guideline:\n",
            "    Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If lovastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin\n",
            "    This guideline applies to the following genes: MT-RNR1\n",
            "\n",
            "    Guideline:\n",
            "    Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: pravastatin\n",
            "    This guideline applies to the following genes: SLCO1B1\n",
            "\n",
            "    Guideline:\n",
            "    Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 poor function phenotype. Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 decreased or possible decreased phenotype. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: imipramine\n",
            "    This guideline applies to the following genes: CYP2C19, CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: atorvastatin\n",
            "    This guideline applies to the following genes: SLCO1B1\n",
            "\n",
            "    Guideline:\n",
            "    Prescribe ≤20mg for patients with SLCO1B1 poor function phenotype and ≤40mg for patients with SLCO1B1 decreased or possible decreased phenotype as a starting dose.  Adjust doses of atorvastatin based on disease-specific guidelines.  Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: desipramine\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: phenytoin\n",
            "    This guideline applies to the following genes: HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    Phenytoin should be avoided if possible in patients with the HLA-B*15:02 allele.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: doxepin\n",
            "    This guideline applies to the following genes: CYP2C19, CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: rosuvastatin\n",
            "    This guideline applies to the following genes: ABCG2, SLCO1B1\n",
            "\n",
            "    Guideline:\n",
            "    Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: antidepressants\n",
            "    This guideline applies to the following genes: CYP2C19, CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends CYP2D6 and CYP2C19 genotyping before initiating an antidepressant treatment, especially in patients with a high risk of toxicity.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: voriconazole\n",
            "    This guideline applies to the following genes: CYP2C19\n",
            "\n",
            "    Guideline:\n",
            "    An alternative antifungal agent should be considered instead of voriconazole in patients who are known to be CYP2C19 ultrarapid metabolizers. CYP2C19 genotyping and use of an alternative antifungal agent is also recommended in patients with subtherapeutic voriconazole serum concentrations despite two dose adjustments.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: pimozide\n",
            "    This guideline applies to the following genes: CYP2D6\n",
            "\n",
            "    Guideline:\n",
            "    Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: abacavir\n",
            "    This guideline applies to the following genes: HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    In individuals with the HLA-B*57:01 variant allele (\"HLA-B*57:01-positive\"), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.\n",
            "\n",
            "    :\n",
            "\n",
            "Please turn the following guideline into an algorithm for an LLM: \n",
            "    This guideline applies to the following medications: allopurinol\n",
            "    This guideline applies to the following genes: HLA-B\n",
            "\n",
            "    Guideline:\n",
            "    Testing for the HLA-B*58:01 allele before starting allopurinol treatment is conditionally recommended for patients of Southeast Asian or African American descent.\n",
            "\n",
            "    :\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "pprint(guidelines_with_algo[:10])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "MCUVKYxc2LgM",
        "outputId": "5f6d5759-03d2-4aee-d614-20dc66491276"
      },
      "execution_count": 110,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[{'algorithm': '1. Check if the medication being prescribed is clomipramine.\\n'\n",
            "               '2. Check if the patient has been tested for the CYP2C19 gene.\\n'\n",
            "               '3. If the patient is an ultrarapid metabolizer (UM) for '\n",
            "               'CYP2C19, then avoid prescribing clomipramine for the '\n",
            "               'indications of Obsessive Compulsive Disorder or Anxiety '\n",
            "               'Disorders.\\n'\n",
            "               '4. If the patient is not an ultrarapid metabolizer (UM) for '\n",
            "               'CYP2C19, then clomipramine can be prescribed for the '\n",
            "               'indications of Obsessive Compulsive Disorder or Anxiety '\n",
            "               'Disorders.',\n",
            "  'guideline': 'The Royal Dutch Pharmacists Association - Pharmacogenetics '\n",
            "               'Working Group (DPWG) recommends to avoid clomipramine in '\n",
            "               'CYP2C19 ultrarapid metabolizer (UM) for Indication OBSESSIVE '\n",
            "               'COMPULSIVE DISORDER or ANXIETY DISORDERS.\\n',\n",
            "  'guideline_id': 'PA166184528',\n",
            "  'name': 'Annotation of DPWG Guideline for clomipramine and CYP2C19',\n",
            "  'relatedChemicals': ['clomipramine'],\n",
            "  'relatedGenes': ['CYP2C19']},\n",
            " {'algorithm': '1. Check if the patient is taking warfarin.\\n'\n",
            "               '2. Check if the patient has been tested for the VKORC1 gene.\\n'\n",
            "               '3. Check the VKORC1 rs9923231 genotype of the patient.\\n'\n",
            "               '4. If the patient has the TT genotype (-1639 AA genotype), '\n",
            "               'calculate the genotype-specific initial dose of warfarin as '\n",
            "               '60% of the standard initial dose.\\n'\n",
            "               '5. Calculate the maintenance dose of warfarin based on the '\n",
            "               \"patient's response to the initial dose.\\n\"\n",
            "               '6. If the patient has the CT genotype (-1639 AG genotype), '\n",
            "               'there are no recommendations for the initial dose or '\n",
            "               'maintenance dose of warfarin.\\n'\n",
            "               \"7. Monitor the patient's response to warfarin and adjust the \"\n",
            "               'dose as necessary.',\n",
            "  'guideline': 'Patients with the VKORC1 rs9923231 TT genotype (-1639 AA '\n",
            "               'genotype) should be given 60% of the standard initial dose of '\n",
            "               'warfarin. The genotype-specific initial dose and maintenance '\n",
            "               'dose can be calculated using an algorithm. There are no '\n",
            "               'recommendation for patients with the VKORC1 rs9923231 CT '\n",
            "               'genotype (-1639 AG genotype).\\n',\n",
            "  'guideline_id': 'PA166182841',\n",
            "  'name': 'Annotation of DPWG Guideline for warfarin and VKORC1',\n",
            "  'relatedChemicals': ['warfarin'],\n",
            "  'relatedGenes': ['VKORC1']},\n",
            " {'algorithm': '1. Check if the patient is taking azathioprine.\\n'\n",
            "               '2. Check if the patient has been tested for TPMT or NUDT15 '\n",
            "               'gene variants.\\n'\n",
            "               '3. If the patient is a poor metabolizer for TPMT or NUDT15, '\n",
            "               'consider an alternate agent or extreme dose reduction of '\n",
            "               'azathioprine.\\n'\n",
            "               '4. If the patient is an intermediate metabolizer for TPMT or '\n",
            "               'NUDT15, start at 30-80% of the target dose for azathioprine.\\n'\n",
            "               '5. Monitor the patient for any adverse effects or changes in '\n",
            "               'response to the medication.\\n'\n",
            "               \"6. Adjust the dose as necessary based on the patient's \"\n",
            "               'individual response and metabolism.',\n",
            "  'guideline': 'Consider an alternate agent or extreme dose reduction of '\n",
            "               'azathioprine for patients who are TPMT or NUDT15 poor '\n",
            "               'metabolizers.  Start at 30-80% of target dose for patients who '\n",
            "               'are TPMT or NUDT15 intermediate metabolizers.\\n',\n",
            "  'guideline_id': 'PA166104933',\n",
            "  'name': 'Annotation of CPIC Guideline for azathioprine and NUDT15, TPMT',\n",
            "  'relatedChemicals': ['azathioprine'],\n",
            "  'relatedGenes': ['NUDT15', 'TPMT']},\n",
            " {'algorithm': '1. Check if the patient is taking rasburicase.\\n'\n",
            "               '2. Check if the patient has been tested for G6PD deficiency.\\n'\n",
            "               '3. If the patient has a negative or inconclusive genetic test '\n",
            "               'result, perform an enzyme activity test to determine G6PD '\n",
            "               'deficiency.\\n'\n",
            "               '4. If the patient is G6PD deficient, do not administer '\n",
            "               'rasburicase.\\n'\n",
            "               '5. If the patient is not G6PD deficient, administer '\n",
            "               'rasburicase as prescribed.\\n'\n",
            "               '6. Note that the G6PD gene is X-linked, so males only have one '\n",
            "               'copy and females have two copies.\\n'\n",
            "               '7. Refer to the full guideline for disclaimers, further '\n",
            "               'details, and supporting evidence.',\n",
            "  'guideline': 'Rasburicase is contraindicated in G6PD deficient patients with '\n",
            "               'or without chronic non-spherocytic hemolytic anemia (CNSHA). '\n",
            "               'In patients with a negative or inconclusive genetic test '\n",
            "               'result an enzyme activity test is recommended prior to '\n",
            "               'rasburicase treatment to determine whether a patient is G6PD '\n",
            "               'deficient. The G6PD gene is X-linked and therefore males only '\n",
            "               'have one copy, whereas females have two copies. See full '\n",
            "               'guideline for disclaimers, further details and supporting '\n",
            "               'evidence.\\n',\n",
            "  'guideline_id': 'PA166119846',\n",
            "  'name': 'Annotation of CPIC Guideline for rasburicase and G6PD',\n",
            "  'relatedChemicals': ['rasburicase'],\n",
            "  'relatedGenes': ['G6PD']},\n",
            " {'algorithm': '1. Check if the patient is taking simvastatin.\\n'\n",
            "               '2. Check if the patient has the SLCO1B1 521 CC or TC '\n",
            "               '(rs4149056) genotype.\\n'\n",
            "               '3. If the patient has the SLCO1B1 521 CC or TC genotype, '\n",
            "               'consider any additional risk factors for statin-induced '\n",
            "               'myopathy.\\n'\n",
            "               '4. Choose an alternative medication for the patient if '\n",
            "               'possible.\\n'\n",
            "               '5. If an alternative medication is not an option for patients '\n",
            "               'with the 521 TC genotype, avoid simvastatin doses exceeding 40 '\n",
            "               'mg/day.\\n'\n",
            "               '6. Advise the patient to contact their doctor if they '\n",
            "               'experience muscle symptoms.',\n",
            "  'guideline': 'Choose an alternative for patients with the SLCO1B1 521 CC or '\n",
            "               'TC (rs4149056) genotype and consider any additional risk '\n",
            "               'factors for statin-induced myopathy.  If an alternative is not '\n",
            "               'an option for patients with the 521 TC genotype, avoid '\n",
            "               'simvastatin doses exceeding 40 mg/day and advise the patient '\n",
            "               'to contact their doctor in the event of muscle symptoms.\\n',\n",
            "  'guideline_id': 'PA166182844',\n",
            "  'name': 'Annotation of DPWG Guideline for simvastatin and SLCO1B1',\n",
            "  'relatedChemicals': ['simvastatin'],\n",
            "  'relatedGenes': ['SLCO1B1']},\n",
            " {'algorithm': '1. Check if the medication is celecoxib, flurbiprofen, '\n",
            "               'ibuprofen, or lornoxicam.\\n'\n",
            "               '2. Check if the gene is CYP2C9.\\n'\n",
            "               '3. If the medication and gene match, determine the metabolizer '\n",
            "               'status of the patient.\\n'\n",
            "               '4. If the patient is a poor metabolizer, initiate therapy with '\n",
            "               '25-50% of the lowest recommended starting dose.\\n'\n",
            "               '5. If the patient is an intermediate metabolizer with an '\n",
            "               'activity score of 1, initiate therapy with the lowest '\n",
            "               'recommended starting dose.\\n'\n",
            "               '6. Refer to the full guideline for further details and '\n",
            "               'supporting evidence.',\n",
            "  'guideline': 'The CPIC Dosing Guideline for celecoxib, flurbiprofen, '\n",
            "               'ibuprofen and lornoxicam recommends initiating therapy with '\n",
            "               '25-50% of\\n'\n",
            "               'the lowest recommended starting dose for CYP2C9 poor '\n",
            "               'metabolizers and initiating therapy with lowest recommended '\n",
            "               'starting dose for CYP2C9 intermediate metabolizers with '\n",
            "               'activity score of 1. See full guideline for further details '\n",
            "               'and supporting evidence.\\n',\n",
            "  'guideline_id': 'PA166191841',\n",
            "  'name': 'Annotation of CPIC Guideline for celecoxib, flurbiprofen, '\n",
            "          'ibuprofen, lornoxicam and CYP2C9',\n",
            "  'relatedChemicals': ['celecoxib', 'flurbiprofen', 'ibuprofen', 'lornoxicam'],\n",
            "  'relatedGenes': ['CYP2C9']},\n",
            " {'algorithm': '1. Check if medication is dexlansoprazole.\\n'\n",
            "               '2. Check if gene is CYP2C19.\\n'\n",
            "               '3. If both conditions are met, follow CPIC Dosing Guideline.\\n'\n",
            "               '4. For CYP2C19 ultrarapid metabolizers, increase starting '\n",
            "               'daily dose and monitor efficacy.\\n'\n",
            "               '5. For CYP2C19 rapid and normal metabolizers treating H. '\n",
            "               'pylori infection and erosive esophagitis, consider increasing '\n",
            "               'dose after initiation with standard starting daily dose.\\n'\n",
            "               '6. For intermediate and poor metabolizers on chronic therapy '\n",
            "               '(>12 weeks), consider 50% reduction in daily dose.\\n'\n",
            "               '7. Refer to full guideline for further details and supporting '\n",
            "               'evidence.',\n",
            "  'guideline': 'The CPIC Dosing Guideline recommendations for dexlansoprazole '\n",
            "               'are based on the similarity in its metabolism and lansoprazole '\n",
            "               'and extrapolated from the first-generation PPIs. The guideline '\n",
            "               'recommends to increase the starting daily dose and to monitor '\n",
            "               'efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid '\n",
            "               'and normal metabolizers in the treatment of H. pylori '\n",
            "               'infection and erosive esophagitis increasing the dose might be '\n",
            "               'considered after initiation with the standard starting daily '\n",
            "               'dose. The recommendations for intermediate and poor '\n",
            "               'metabolizers for chronic therapy (>12 weeks) and efficacy '\n",
            "               'achieved is to consider 50% reduction in daily dose. See full '\n",
            "               'guideline for further details and supporting evidence.\\n',\n",
            "  'guideline_id': 'PA166219301',\n",
            "  'name': 'Annotation of CPIC Guideline for dexlansoprazole and CYP2C19',\n",
            "  'relatedChemicals': ['dexlansoprazole'],\n",
            "  'relatedGenes': ['CYP2C19']},\n",
            " {'algorithm': '1. Check if the medication being prescribed is voriconazole.\\n'\n",
            "               '2. Check if the patient has a genetic variation in the CYP2C19 '\n",
            "               'gene.\\n'\n",
            "               '3. If the patient is an ultrarapid metabolizer, rapid '\n",
            "               'metabolizer, or poor metabolizer of CYP2C19:\\n'\n",
            "               '   a. For adult patients, select an alternative medication '\n",
            "               'that is not dependent on CYP2C19 metabolism.\\n'\n",
            "               '   b. For pediatric patients, select an alternative medication '\n",
            "               'if they are ultrarapid metabolizers or poor metabolizers.\\n'\n",
            "               '4. If the patient is a rapid metabolizer and a pediatric '\n",
            "               'patient:\\n'\n",
            "               '   a. Initiate therapy at recommended standard case dosing.\\n'\n",
            "               '   b. Use therapeutic dosing monitoring to titrate the dose to '\n",
            "               'therapeutic trough concentrations.',\n",
            "  'guideline': 'The CPIC dosing guideline for voriconazole recommends '\n",
            "               'selecting an alternative agent that is not dependent on '\n",
            "               'CYP2C19 metabolism in adults who are CYP2C19 ultrarapid '\n",
            "               'metabolizers, rapid metabolizers or poor metabolizers. In '\n",
            "               'pediatric patients, an alternative agent should be used in '\n",
            "               'patients who are ultrarapid metabolizers or poor metabolizers. '\n",
            "               'In pediatric rapid metabolizers, therapy should be initiated '\n",
            "               'at recommended standard case dosing, then therapeutic dosing '\n",
            "               'monitoring should be used to titrate dose to therapeutic '\n",
            "               'trough concentrations.\\n',\n",
            "  'guideline_id': 'PA166161537',\n",
            "  'name': 'Annotation of CPIC Guideline for voriconazole and CYP2C19',\n",
            "  'relatedChemicals': ['voriconazole'],\n",
            "  'relatedGenes': ['CYP2C19']},\n",
            " {'algorithm': '1. Check if the patient has been diagnosed with cystic '\n",
            "               'fibrosis.\\n'\n",
            "               '2. Check if the patient has been tested for CFTR variants.\\n'\n",
            "               '3. If the patient is homozygous or heterozygous for CFTR '\n",
            "               'variants that have been shown to respond to ivacaftor '\n",
            "               'treatment, then ivacaftor treatment is recommended.\\n'\n",
            "               '4. If the patient is not homozygous or heterozygous for CFTR '\n",
            "               'variants that have been shown to respond to ivacaftor '\n",
            "               'treatment, then ivacaftor treatment is not recommended.\\n'\n",
            "               '5. Refer to the full guideline for disclaimers, further '\n",
            "               'details, and supporting evidence.',\n",
            "  'guideline': 'Ivacaftor treatment is recommended only in cystic fibrosis '\n",
            "               '(CF) patients that are either homozygous or heterozygous for '\n",
            "               'certain CFTR variants.  See full guideline for disclaimers, '\n",
            "               'further details and supporting evidence.\\n',\n",
            "  'guideline_id': 'PA166114461',\n",
            "  'name': 'Annotation of CPIC Guideline for ivacaftor and CFTR',\n",
            "  'relatedChemicals': ['ivacaftor'],\n",
            "  'relatedGenes': ['CFTR']},\n",
            " {'algorithm': '1. Check if the medication in question is clopidogrel.\\n'\n",
            "               '2. Check if the gene in question is CYP2C19.\\n'\n",
            "               '3. Determine if the patient is a poor or intermediate '\n",
            "               'metabolizer of CYP2C19.\\n'\n",
            "               '4. If the patient is a poor or intermediate metabolizer, '\n",
            "               'consider alternative antiplatelet therapy.\\n'\n",
            "               '5. For cardiovascular indications, consider prasugrel or '\n",
            "               'ticagrelor if there are no contraindications.\\n'\n",
            "               '6. For neurovascular indications, consider an alternative '\n",
            "               'P2Y12 inhibitor if clinically indicated and there are no '\n",
            "               'contraindications.',\n",
            "  'guideline': 'The CPIC Dosing Guideline for clopidogrel recommends an '\n",
            "               'alternative antiplatelet therapy for CYP2C19 poor or '\n",
            "               'intermediate metabolizers (cardiovascular indications: '\n",
            "               'prasugrel or ticagrelor if no contraindication; neurovascular '\n",
            "               'indications: alternative P2Y12 inhibitor if clinically '\n",
            "               'indicated and no contraindication.)\\n',\n",
            "  'guideline_id': 'PA166104948',\n",
            "  'name': 'Annotation of CPIC Guideline for clopidogrel and CYP2C19',\n",
            "  'relatedChemicals': ['clopidogrel'],\n",
            "  'relatedGenes': ['CYP2C19']}]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "len(guidelines_with_algo)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "1ZMoDX_r92u5",
        "outputId": "babe0083-7d1b-4f81-ef6b-7eda3467160d"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "134"
            ]
          },
          "metadata": {},
          "execution_count": 51
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "guidelines_with_algo_filename = '/content/drive/MyDrive/pgx/guidelines_with_algo_v2.csv'"
      ],
      "metadata": {
        "id": "UGPY3uUg9Nq2"
      },
      "execution_count": 108,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import csv\n",
        "\n",
        "header = guidelines_with_algo[0].keys()\n",
        "# Open a CSV file for writing\n",
        "with open(guidelines_with_algo_filename, 'w', newline='') as csvfile:\n",
        "  # Create a writer object\n",
        "  writer = csv.writer(csvfile)\n",
        "\n",
        "  # Write the header row\n",
        "  writer.writerow(header)\n",
        "\n",
        "  # Write the data rows\n",
        "  for row in guidelines_with_algo:\n",
        "      writer.writerow(row.values())"
      ],
      "metadata": {
        "id": "jZYMNdwq0NSx"
      },
      "execution_count": 109,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": 116,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "BJVPRqO-LMnZ",
        "outputId": "26978d1f-46ca-4718-8fb5-230e064624af"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<weaviate.batch.crud_batch.Batch at 0x7fed7453beb0>"
            ]
          },
          "metadata": {},
          "execution_count": 116
        }
      ],
      "source": [
        "client.batch.configure(\n",
        "    batch_size=5, \n",
        "    dynamic=True,\n",
        "    timeout_retries=3,\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 117,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "K_dR3YLFTHtw",
        "outputId": "e99b9c21-2b71-4be8-ed02-8b0ee6fe04e4"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Import 0 / 134 \n",
            "Import 5 / 134 \n",
            "Import 10 / 134 \n",
            "Import 15 / 134 \n",
            "Import 20 / 134 \n",
            "Import 25 / 134 \n",
            "Import 30 / 134 \n",
            "Import 35 / 134 \n",
            "Import 40 / 134 \n",
            "Import 45 / 134 \n",
            "Import 50 / 134 \n",
            "Import 55 / 134 \n",
            "Import 60 / 134 \n",
            "Import 65 / 134 \n",
            "Import 70 / 134 \n",
            "Import 75 / 134 \n",
            "Import 80 / 134 \n",
            "Import 85 / 134 \n",
            "Import 90 / 134 \n",
            "Import 95 / 134 \n",
            "Import 100 / 134 \n",
            "Import 105 / 134 \n",
            "Import 110 / 134 \n",
            "Import 115 / 134 \n",
            "Import 120 / 134 \n",
            "Import 125 / 134 \n",
            "Import 130 / 134 \n"
          ]
        }
      ],
      "source": [
        "import time\n",
        "counter=0\n",
        "\n",
        "with client.batch as batch:\n",
        "  for guideline in guidelines_with_algo:\n",
        "      if (counter %5 == 0):\n",
        "          print(f\"Import {counter} / {len(guidelines)} \")\n",
        "      \n",
        "      batch.add_data_object(guideline, \"Guideline\")\n",
        "      counter = counter+1\n",
        "      time.sleep(5)\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 118,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "vsB-NAYYTtin",
        "outputId": "f7abcd98-0700-4303-c52d-43eec56dc175"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Object count:  [{'meta': {'count': 134}}] \n",
            "\n"
          ]
        }
      ],
      "source": [
        "result = (\n",
        "    client.query.aggregate(\"Guideline\")\n",
        "    .with_fields(\"meta { count }\")\n",
        "    .do()\n",
        ")\n",
        "print(\"Object count: \", result[\"data\"][\"Aggregate\"][\"Guideline\"], \"\\n\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "0NGPElCpT5kP",
        "outputId": "e05ddd55-1831-473d-c772-7beb96b07ac9"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'guideline': 'The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for TPMT gene variants when prescribing cisplatin in pediatric cancer patients. They recommend testing for the TPMT alleles *2, *3A, *3B or *3C in all pediatric cancer patients due to the association of these alleles with an increased risk of cisplatin-induced ototoxicity.\\n', 'name': 'Annotation of CPNDS Guideline for cisplatin and TPMT', 'relatedChemicals': ['cisplatin'], 'relatedGenes': ['TPMT']}\n"
          ]
        }
      ],
      "source": [
        "# Test one article has worked by checking one object\n",
        "test_guideline = (\n",
        "    client.query\n",
        "    .get(\"Guideline\", [\"name\", \"relatedGenes\", \"guideline\", \"relatedChemicals\"])\n",
        "    .with_limit(1)\n",
        "    .do()\n",
        ")[\"data\"][\"Get\"][\"Guideline\"][0]\n",
        "\n",
        "print(test_guideline)\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "3DEStwe2WkRM"
      },
      "outputs": [],
      "source": [
        "nearText = {\"concepts\": [\"Patient is a poor metabolizer of CYP2C19. Patient is taking citalopram.\"]}\n",
        "\n",
        "result = (\n",
        "    client.query\n",
        "    .get(\"Guideline\", [\"name\", \"relatedGenes\", \"guideline\", \"relatedChemicals\", \"algorithm\"])\n",
        "    .with_near_text(nearText)\n",
        "    .with_limit(2)\n",
        "    .do()\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Q998-iBUW93S",
        "outputId": "673c8efa-5fb5-45a9-fa65-3822abb2dd84"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[{'algorithm': '1. Check if the patient is a CYP2C19 ultrarapid metabolizer.\\n'\n",
            "               '2. If the patient is a CYP2C19 ultrarapid metabolizer, '\n",
            "               'recommend an alternative drug not predominantly metabolized by '\n",
            "               'CYP2C19.\\n'\n",
            "               '3. If the patient is not a CYP2C19 ultrarapid metabolizer, '\n",
            "               'check if the patient is a CYP2C19 poor metabolizer.\\n'\n",
            "               '4. If the patient is a CYP2C19 poor metabolizer, consider a '\n",
            "               '50% reduction of recommended starting dose.\\n'\n",
            "               '5. Titrate the dose to response or select an alternative drug '\n",
            "               'not predominantly metabolized by CYP2C19.\\n'\n",
            "               '6. Monitor the patient for adverse effects and adjust the dose '\n",
            "               'as necessary.',\n",
            "  'guideline': 'The CPIC Dosing Guideline for the selective serotonin reuptake '\n",
            "               'inhibitors citalopram and escitalopram recommends an '\n",
            "               'alternative drug not predominantly metabolized by CYP2C19 for '\n",
            "               'CYP2C19 ultrarapid metabolizers. For CYP2C19 poor '\n",
            "               'metabolizers, consider a 50% reduction of recommended starting '\n",
            "               'dose and titrate to response or select alternative drug not '\n",
            "               'predominantly metabolized by CYP2C19.\\n',\n",
            "  'name': 'Annotation of CPIC Guideline for citalopram,escitalopram and '\n",
            "          'CYP2C19',\n",
            "  'relatedChemicals': ['citalopram', 'escitalopram'],\n",
            "  'relatedGenes': ['CYP2C19']},\n",
            " {'algorithm': \"1. Check patient's CYP2C19 genotype to determine if they are a \"\n",
            "               'poor metabolizer.\\n'\n",
            "               '2. If patient is a poor metabolizer, do not exceed a dose of '\n",
            "               '75 mg/day.\\n'\n",
            "               '3. Start with a lower dose and gradually increase based on '\n",
            "               'patient response and side effects.\\n'\n",
            "               \"4. Monitor patient's sertraline plasma concentration to guide \"\n",
            "               'dose adjustments.\\n'\n",
            "               '5. If patient experiences adverse effects, consider reducing '\n",
            "               'the dose or discontinuing the medication.\\n'\n",
            "               \"6. Continue to monitor patient's response and adjust dose as \"\n",
            "               'necessary.',\n",
            "  'guideline': 'Do not give doses exceeding 75 mg/day in patients with CYP2C19 '\n",
            "               'poor metabolizer genotypes, and guide the dose by response and '\n",
            "               'side effects and/or sertraline plasma concentration.\\n',\n",
            "  'name': 'Annotation of DPWG Guideline for sertraline and CYP2C19',\n",
            "  'relatedChemicals': ['sertraline'],\n",
            "  'relatedGenes': ['CYP2C19']}]\n"
          ]
        }
      ],
      "source": [
        "pprint(result['data']['Get']['Guideline'])"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "results"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "TYGi4Hj4ywub",
        "outputId": "80d363a5-e5fa-49e9-fc30-a8c90a57afb4"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[\"1. Input: Patient's CYP2C19 metabolizer status (intermediate or poor) and the Dutch Pharmacogenetics Working Group (DPWG) document containing specified daily doses for citalopram.\\n\\n2. Check if the patient's CYP2C19 metabolizer status is either intermediate or poor.\\n   a. If the patient's status is not intermediate or poor, proceed with the standard citalopram dosing recommendations.\\n   b. If the patient's status is intermediate or poor, proceed to step 3.\\n\\n3. Retrieve the specified daily doses for citalopram from the DPWG document.\\n\\n4. Determine the maximum daily dose for the patient based on their CYP2C19 metabolizer status:\\n   a. If the patient is an intermediate metabolizer, assign the maximum daily dose for intermediate metabolizers from the DPWG document.\\n   b. If the patient is a poor metabolizer, assign the maximum daily dose for poor metabolizers from the DPWG document.\\n\\n5. Output: The recommended maximum daily dose of citalopram for the patient based on their CYP2C19 metabolizer status.\",\n",
              " \"1. Obtain the patient's CYP2C19 genotype information.\\n2. Check if the patient has a poor metabolizer genotype for CYP2C19.\\n3. If the patient has a poor metabolizer genotype, proceed to step 4. If not, follow the standard dosing guidelines.\\n4. Start the patient on a lower initial dose of sertraline, considering their specific needs and medical history.\\n5. Monitor the patient's response to the medication, including any side effects experienced.\\n6. Obtain sertraline plasma concentration data for the patient, if available.\\n7. If the patient experiences significant side effects or inadequate response to the medication, adjust the dose accordingly, ensuring that the daily dose does not exceed 75 mg.\\n8. Continue to monitor the patient's response and side effects, adjusting the dose as needed while keeping the daily dose below 75 mg.\\n9. If the patient's response remains inadequate or side effects persist despite dose adjustments, consider alternative treatment options or consult a specialist for further guidance.\"]"
            ]
          },
          "metadata": {},
          "execution_count": 37
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "prompt = \"Turn the following guideline into an algorithm: {algorithm}\""
      ],
      "metadata": {
        "id": "TcTSlPfbL5Xf"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "uBZKpYrwcnVb"
      },
      "outputs": [],
      "source": [
        "result = (\n",
        "  client.query\n",
        "  .get(\"Guideline\", [\"algorithm\"])\n",
        "  .with_near_text(nearText)\n",
        "  .with_limit(1)\n",
        "  .with_generate(single_prompt=prompt)\n",
        ").do()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "tx880Vu0ebRp",
        "outputId": "9aa89349-c536-45d8-963c-6d710e90fffa"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'data': {'Get': {'Guideline': None}},\n",
            " 'errors': [{'locations': [{'column': 6, 'line': 1}],\n",
            "             'message': 'explorer: get class: extend: extend generate: wrong '\n",
            "                        'parameters',\n",
            "             'path': ['Get', 'Guideline']}]}\n"
          ]
        }
      ],
      "source": [
        "pprint(result)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/drive')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "yKfr9rW4JdPK",
        "outputId": "8a157193-7fe1-4005-c788-7a123706020e"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Mounted at /content/drive\n"
          ]
        }
      ]
    }
  ],
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}